Analyst consensus rating
Avalo Therapeutics Analyst Rating: Strong Buy
Direct answer
Avalo Therapeutics's consensus rating is Strong Buy.
12 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $44.08.
Forecast evidence checked September 9, 2026.
Get free Avalo Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $19.71
- Average price target
- $44.08
- High price target
- $60.00
- Low price target
- $30.00
- Low target gap
- +52.2%
- Target upside
- +123.7%
- High target gap
- +204.4%
- Target range width
- 152.2%
- Consensus rating
- Strong Buy
- Analysts
- 12
- Evidence date
- September 9, 2026
- Valid through
- September 16, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Avalo Therapeutics?
Avalo Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $44.08.
How far are Avalo Therapeutics's low and high targets from the recorded price?
The low target implies +52.2%, while the high target implies +204.4%.
How many analysts are included in Avalo Therapeutics's consensus?
The verified consensus includes 12 analysts.
How is Avalo Therapeutics's target upside or downside calculated?
The average target of $44.08 is divided by the recorded price of $19.71, then one is subtracted to produce +123.7%. This does not guarantee a future return.
When was Avalo Therapeutics's analyst forecast verified?
The data was verified on 2026-09-09. The dataset is valid through 2026-09-16.